Compounds > triamcinolone
Page last updated: 2024-08-23

triamcinolone and Angiogenesis, Pathologic

triamcinolone has been researched along with Angiogenesis, Pathologic in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jager, MJ; Missotten, GS; Schlingemann, RO1
Blodi, BA; Chan, CK; Ip, MS; Oden, NL; Scott, IU; Tolentino, MJ; Vanveldhuisen, PC1
Beeley, NR; de Juan, E; Fujii, GY; Mahmoud, MI; Mello-Filho, PA; Rossi, JV; Varner, SE1
Cho, GJ; Choi, MY; Choi, WS; Chung, IY; Kang, SS; Kim, YH; Kim, YS; Lee, JH; Park, CH; Roh, GS; Yoo, JM1
Brilla, C; Funck, RC; Grimm, W; Herzum, M; Hufnagel, G; Maisch, B; Pankuweit, S; Simon, BC1

Trials

1 trial(s) available for triamcinolone and Angiogenesis, Pathologic

ArticleYear
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.
    Ophthalmology, 2011, Volume: 118, Issue:7

    Topics: Aged; Capillaries; Female; Glaucoma, Neovascular; Glucocorticoids; Humans; Incidence; Iris; Ischemia; Light Coagulation; Linear Models; Male; Neovascularization, Pathologic; Retinal Hemorrhage; Retinal Neovascularization; Retinal Vein Occlusion; Retinal Vessels; Risk Assessment; Triamcinolone; Vitreous Hemorrhage

2011

Other Studies

4 other study(ies) available for triamcinolone and Angiogenesis, Pathologic

ArticleYear
Angiogenesis and vascular endothelial growth factors in intraocular tumors.
    Developments in ophthalmology, 2010, Volume: 46

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Chronic Disease; Eye Neoplasms; Glaucoma, Neovascular; Glucocorticoids; Humans; Inflammation; Injections, Intraocular; Neovascularization, Pathologic; Radiation Injuries; Ranibizumab; Retinal Diseases; Triamcinolone; Vascular Endothelial Growth Factor A

2010
Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant.
    Journal of biomedical materials research. Part A, 2005, Jun-15, Volume: 73, Issue:4

    Topics: Absorbable Implants; Angiography; Animals; Aqueous Humor; Biocompatible Materials; Cell Proliferation; Choroid; Drug Delivery Systems; Drug Implants; Neovascularization, Pathologic; Polyesters; Polymers; Prostheses and Implants; Prosthesis Implantation; Rabbits; Retina; Serum Albumin, Bovine; Steroids; Time Factors; Triamcinolone

2005
Triamcinolone suppresses retinal vascular pathology via a potent interruption of proinflammatory signal-regulated activation of VEGF during a relative hypoxia.
    Neurobiology of disease, 2007, Volume: 26, Issue:3

    Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Body Weight; Cytokines; Disease Models, Animal; Encephalitis; Female; Gene Expression Regulation; Hyperoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Inflammation Mediators; Neovascularization, Pathologic; Oxidative Stress; Oxygen; Rats; Rats, Sprague-Dawley; Retinal Artery; Retinal Diseases; Signal Transduction; Triamcinolone; Vascular Endothelial Growth Factor A

2007
Intrapericardial treatment of inflammatory and neoplastic pericarditis guided by pericardioscopy and epicardial biopsy--results from a pilot study.
    Clinical cardiology, 1999, Volume: 22, Issue:1 Suppl 1

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Autoimmune Diseases; Bacterial Infections; Biopsy; Cisplatin; Endoscopy; Female; Fibrin; Glucocorticoids; Humans; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Paracentesis; Pericardial Effusion; Pericarditis; Pericardium; Pilot Projects; Sensitivity and Specificity; Survival Rate; Triamcinolone

1999